IMPORTANCE: X-linked retinitis pigmentosa is a severe inherited retinal degenerative disease with a frequency of 1 in 100,000 persons. Because no cure is available for this orphan disease and treatment options are limited, slowing of disease progression would be a meaningful outcome. OBJECTIVE: To determine whether high-dose docosahexaenoic acid (DHA), an ω-3 polyunsaturated fatty acid, slows progression of X-linked retinitis pigmentosa measured by cone electroretinography (ERG). DESIGN, SETTING, AND PARTICIPANTS: A 4-year, single-site, randomized, placebo-controlled, double-masked phase 2 clinical trial at a research center specializing in medical retina. Seventy-eight male patients diagnosed as having X-linked retinitis pigmentosa were randomized to DHA or placebo. Data were omitted for 2 patients with non-X-linked retinitis pigmentosa and 16 patients who were unable to follow protocol during the first year. The remaining participants were tested annually and composed a modified intent-to-treat cohort (DHA group, n = 33; placebogroup, n = 27). INTERVENTIONS: All participants received a multivitamin and were randomly assigned to oral DHA (30 mg/kg/d) or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was the rate of loss of cone ERG function. Secondary outcomes were rod and maximal ERG amplitudes and cone ERG implicit times. Capsule counts and red blood cellDHA levels were assessed to monitor adherence. RESULTS:Average (6-month to 4-year) red blood cellDHA levels were 4-fold higher in the DHA group than in the placebo group (P < .001). There was no difference between the DHA and placebo groups in the rate of cone ERG functional loss (0.028 vs 0.022 log µV/y, respectively; P = .30). No group differences were evident for change in rod ERG (P = .27), maximal ERG (P = .65), or cone implicit time (no change over 4 years). The rate of cone loss (ie, event rate) was markedly reduced compared with rates in previous studies. No severe treatment-emergent adverse events were found. CONCLUSIONS AND RELEVANCE: Long-term DHA supplementation was not effective in slowing the loss of cone or rod ERG function associated with X-linked retinitis pigmentosa. Participant dropout and lower-than-expected disease event rate limited power to detect statistical significance. A larger sample size, longer trial, and attainment of a target blood DHA level (13%) would be desirable. While DHA supplementation at 30 mg/kg/d does not present serious adverse effects, routine monitoring of gastrointestinal tolerance is prudent. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00100230.
RCT Entities:
IMPORTANCE: X-linked retinitis pigmentosa is a severe inherited retinal degenerative disease with a frequency of 1 in 100,000 persons. Because no cure is available for this orphan disease and treatment options are limited, slowing of disease progression would be a meaningful outcome. OBJECTIVE: To determine whether high-dose docosahexaenoic acid (DHA), an ω-3 polyunsaturated fatty acid, slows progression of X-linked retinitis pigmentosa measured by cone electroretinography (ERG). DESIGN, SETTING, AND PARTICIPANTS: A 4-year, single-site, randomized, placebo-controlled, double-masked phase 2 clinical trial at a research center specializing in medical retina. Seventy-eight male patients diagnosed as having X-linked retinitis pigmentosa were randomized to DHA or placebo. Data were omitted for 2 patients with non-X-linked retinitis pigmentosa and 16 patients who were unable to follow protocol during the first year. The remaining participants were tested annually and composed a modified intent-to-treat cohort (DHA group, n = 33; placebo group, n = 27). INTERVENTIONS: All participants received a multivitamin and were randomly assigned to oral DHA (30 mg/kg/d) or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was the rate of loss of cone ERG function. Secondary outcomes were rod and maximal ERG amplitudes and cone ERG implicit times. Capsule counts and red blood cell DHA levels were assessed to monitor adherence. RESULTS: Average (6-month to 4-year) red blood cell DHA levels were 4-fold higher in the DHA group than in the placebo group (P < .001). There was no difference between the DHA and placebo groups in the rate of cone ERG functional loss (0.028 vs 0.022 log µV/y, respectively; P = .30). No group differences were evident for change in rod ERG (P = .27), maximal ERG (P = .65), or cone implicit time (no change over 4 years). The rate of cone loss (ie, event rate) was markedly reduced compared with rates in previous studies. No severe treatment-emergent adverse events were found. CONCLUSIONS AND RELEVANCE: Long-term DHA supplementation was not effective in slowing the loss of cone or rod ERG function associated with X-linked retinitis pigmentosa. Participant dropout and lower-than-expected disease event rate limited power to detect statistical significance. A larger sample size, longer trial, and attainment of a target blood DHA level (13%) would be desirable. While DHA supplementation at 30 mg/kg/d does not present serious adverse effects, routine monitoring of gastrointestinal tolerance is prudent. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00100230.
Authors: C Ayuso; M J Trujillo; M Robledo; C Ramos; J Benitez; F Martín-Osés; T del Rio; B García-Sandoval Journal: Hum Genet Date: 1996-07 Impact factor: 4.132
Authors: Abigail T Fahim; Sara J Bowne; Lori S Sullivan; Kaylie D Webb; Jessica T Williams; Dianna K Wheaton; David G Birch; Stephen P Daiger Journal: Adv Exp Med Biol Date: 2012 Impact factor: 2.622
Authors: Dennis R Hoffman; Richard C Theuer; Yolanda S Castañeda; Dianna H Wheaton; Rain G Bosworth; Anna R O'Connor; Sarah E Morale; Lindsey E Wiedemann; Eileen E Birch Journal: J Nutr Date: 2004-09 Impact factor: 4.798
Authors: Giuseppe Querques; Pascale Benlian; Bernard Chanu; Nicolas Leveziel; Gabriel Coscas; Gisele Soubrane; Eric H Souied Journal: Clin Ophthalmol Date: 2010-07-21
Authors: Dennis R Hoffman; Kirsten G Locke; Dianna H Wheaton; Gary E Fish; Rand Spencer; David G Birch Journal: Am J Ophthalmol Date: 2004-04 Impact factor: 5.258
Authors: J Thomas Brenna; Behzad Varamini; Robert G Jensen; Deborah A Diersen-Schade; Julia A Boettcher; Linda M Arterburn Journal: Am J Clin Nutr Date: 2007-06 Impact factor: 7.045
Authors: Cindy X Cai; Kirsten G Locke; Rithambara Ramachandran; David G Birch; Donald C Hood Journal: Invest Ophthalmol Vis Sci Date: 2014-10-23 Impact factor: 4.799
Authors: Dennis R Hoffman; Dianna K Hughbanks-Wheaton; Rand Spencer; Gary E Fish; N Shirlene Pearson; Yi-Zhong Wang; Martin Klein; Alison Takacs; Kirsten G Locke; David G Birch Journal: Invest Ophthalmol Vis Sci Date: 2015-10 Impact factor: 4.799
Authors: Eliot L Berson; Carol Weigel-DiFranco; Bernard Rosner; Alexander R Gaudio; Michael A Sandberg Journal: JAMA Ophthalmol Date: 2018-05-01 Impact factor: 7.389
Authors: David G Birch; Kirsten G Locke; Joost Felius; Martin Klein; Dianna K H Wheaton; Dennis R Hoffman; Donald C Hood Journal: Ophthalmology Date: 2014-12-31 Impact factor: 12.079
Authors: N Brito-García; T Del Pino-Sedeño; M M Trujillo-Martín; R M Coco; E Rodríguez de la Rúa; I Del Cura-González; P Serrano-Aguilar Journal: Eye (Lond) Date: 2016-12-09 Impact factor: 3.775
Authors: Dianna K Hughbanks-Wheaton; David G Birch; Gary E Fish; Rand Spencer; N Shirlene Pearson; Alison Takacs; Dennis R Hoffman Journal: Invest Ophthalmol Vis Sci Date: 2014-07-11 Impact factor: 4.799
Authors: Ioannis S Dimopoulos; Stephanie Chan; Robert E MacLaren; Ian M MacDonald Journal: Expert Opin Orphan Drugs Date: 2015-07-01 Impact factor: 0.694